RecruitingNot applicableNCT06182748
Physical Activity and Fibrosing Interstitial Lung Disease
Studying Interstitial lung disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Intervention
- Training on eccentric ergocycle(other)
- Enrollment
- 60 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (1)
- Exercise and Sports Medicine Department, Bobigny, Seine Saint Denis, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06182748 on ClinicalTrials.govOther trials for Interstitial lung disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07398287Efficacy of L-menthol on Breathlessness in Interstitial Lung DiseaseRegion Skane
- RECRUITINGNANCT07283081Impact of Capillaroscopy in the Investigation of Diffuse Interstitial PneumoniasUniversity Hospital, Bordeaux
- RECRUITINGNANCT07254338Exploration of Metabolome in Patients With Interstitial Lung Disease and Pulmonary Hypertension With or Without Specific Pulmonary Hypertension TreatmentHospices Civils de Lyon
- RECRUITINGPHASE1NCT07372989Nebulized Human Amniotic Fluid in Patients With Interstitial Lung DiseaseMaule Stem Cell Research Institute, Inc.
- RECRUITINGPHASE1NCT06992661A Study of the Pharmacokinetics and Safety of Single-dose Inhaled RJ026 in Healthy Volunteers and Patients With Interstitial Lung DiseaseRuijin Hospital
- RECRUITINGNANCT07301697Safety and Performance Profile of Cryobiopsy in Bronchial EndoscopyUniversity Hospital, Strasbourg, France
- RECRUITINGNANCT07300696Functional MRI for Monitoring Progression and Assessing Trends in ILDUniversity Hospital Heidelberg
- RECRUITINGPHASE3NCT06806592A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic DiseasesBoehringer Ingelheim